苏州金鸿顺汽车部件股份有限公司 关于金鸿顺 2024 年年度报告的信息披露监管问询函 的回复公告 证券代码：603922 证券简称：金鸿顺 公告编号：2025-034 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 苏州金鸿顺汽车部件股份有限公司（以下简称"公司"），于近日收到上海证 券交易所出具的《关于苏州金鸿顺汽车部件股份有限公司 2024 年年度报告的信 息披露监管问询函》（上证公函【2025】0622 号，以下简称"《问询函》"）。公 司收到《问询函》后高度重视，积极组织相关各方就《问询函》中所涉及事项逐 项进行了认真的核实、分析和研究，现将《问询函》的部分主要内容及公司回复 公告如下： 一、关于业绩波动。年报显示，公司主营业务为汽车车身和底盘冲压零部 件及其相关模具的开发、生产与销售。2024 年公司实现营业收入 8.67 亿元，同 比增长 87.21%，实现归母净利润-0.12 亿元，近四年盈亏交替，扣非后归母净利 润-0.26 亿元，已连续六年为负。分业务看，汽车零部件业务报告期销售量合计 3,730.09 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 证券代码：603922 证券简称：金鸿顺 公告编号：2025-032 苏州金鸿顺汽车部件股份有限公司 2025年半年度业绩预告 重要内容提示： 1、苏州金鸿顺汽车部件股份有限公司（以下简称"公司"）预计2025年半年度实现归属于上市公司股东 的净利润为580.00万元到865.00万元，同比增加146.69%到169.64%。 2、公司预计2025年半年度实现归属于上市公司股东的扣除非经常性损益的净利润为390.00万元到584.00 万元，同比增加118.97%到128.41%。 一、本期业绩预告情况 （一）业绩预告期间 2025年1月1日至2025年6月30日。 （二）业绩预告情况 1、经财务部初步测算，预计2025年半年度经营业绩将出现盈利，实现归属于上市公司股东的净利润为 580.00万元到865.00万元，同比增加146.69%到169.64%。 2、公司预计2025年半年度实现归属于上市公司股东的扣除非经常性损益的净利润为390.00万元到584.00 万元，同 ...

证券代码：603922 证券简称：金鸿顺 公告编号：2025-033 苏州金鸿顺汽车部件股份有限公司 2025 年半年度业绩预告补充更正公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 苏州金鸿顺汽车部件股份有限公司（以下简称"公司"）于本日披露了《金 鸿顺2025年半年度业绩预告》（公告编号：2025-032），由于公告文中对于2025年 半年度业绩波动同比描述易产生歧义，公司现对该公告补充更正如下： 原公告内容为： 重要内容提示： 现补充更正为： 重要内容提示： 1、苏州金鸿顺汽车部件股份有限公司（以下简称"公司"）预计 2025 年半年 度实现归属于上市公司股东的净利润为 580.00 万元到 865.00 万元，同比增加 146.69%到 169.64%。 2、公司预计 2025 年半年度实现归属于上市公司股东的扣除非经常性损益的 净利润为 390.00 万元到 584.00 万元，同比增加 118.97%到 128.41%。 一、本期业绩预告情况 …… （二）业绩预告情况 1、经财务部初步测算，预计 202 ...

证券代码：603922 证券简称：金鸿顺 公告编号：2025-033 苏州金鸿顺汽车部件股份有限公司 2025 年半年度业绩预告补充更正公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 苏州金鸿顺汽车部件股份有限公司（以下简称"公司"）于本日披露了《金 鸿顺2025年半年度业绩预告》（公告编号：2025-032），由于公告文中对于2025年 半年度业绩波动同比描述易产生歧义，公司现对该公告补充更正如下： 原公告内容为： 重要内容提示： 1、苏州金鸿顺汽车部件股份有限公司（以下简称"公司"）预计 2025 年半年 度实现归属于上市公司股东的净利润为 580.00 万元到 865.00 万元，同比增加 146.69%到 169.64%。 2、公司预计 2025 年半年度实现归属于上市公司股东的扣除非经常性损益的 净利润为 390.00 万元到 584.00 万元，同比增加 118.97%到 128.41%。 一、本期业绩预告情况 …… （二）业绩预告情况 1、经财务部初步测算，预计 2025 年半年度经营业绩将出现盈利， ...

证券代码：603922 证券简称：金鸿顺 公告编号：2025-032 苏州金鸿顺汽车部件股份有限公司 2025 年半年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 1、苏州金鸿顺汽车部件股份有限公司（以下简称"公司"）预计 2025 年半年 度实现归属于上市公司股东的净利润为 580.00 万元到 865.00 万元，同比增加 146.69%到 169.64%。 2、公司预计 2025 年半年度实现归属于上市公司股东的扣除非经常性损益的 净利润为 390.00 万元到 584.00 万元，同比增加 118.97%到 128.41%。 一、本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 6 月 30 日。 （二）业绩预告情况 二、上年同期业绩情况 （一）归属于上市公司股东的净利润：-1,242.14 万元；归属于上市公司股东 的扣除非经常性损益的净利润：-2,055.39 万元。 （二）每股收益：-0.10 元。 三、本期业绩预盈的主要原因 2025 年半年 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示: 截至本公告披露日，苏州金鸿顺汽车部件股份有限公司（以下简称"公司"） 的控股股东海南众德科技有限公司（以下简称"众德科技"）持有公司股份 53,742,080 股，占公司目前总股本的 29.99%。本次部分股份质押后，众德科 技累计质押股份数量为 41,471,000 股，累计质押数量占其持有公司总股数的 77.1667%，占公司总股本的 23.1423%。 一、公司股份质押 （一）本次股份质押基本情况 | 股东名称 | 是否为控 | 本次质押 | 是否为限 | 是否补 | 质押起始日 | 质押到期日 | 质权人 | 占其所持 | 占公司总 | 质押融资 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 股股东 | 股数 | 售股 | 充质押 | | | | 股份比例 | 股本比例 | 资金用途 | | 海南众德科 技有限公司 | 是 | 5,000,000 | ...

Group 1 - The company held an investor briefing regarding the termination of a major asset restructuring plan on July 2025, which was conducted online [1][2] - The chairman, independent director, CFO, and board secretary addressed investor concerns and provided responses within the limits of information disclosure [1] - The company confirmed that the second quarter operating performance and mid-year report details would be available in August 2025 [1] Group 2 - The reason for terminating the major asset restructuring was due to the inability of the parties involved to reach a consensus on the final transaction plan after multiple negotiations [1] - The company emphasized that it conducted thorough research and friendly negotiations with relevant parties before deciding to terminate the restructuring [1] - The company reassured investors that its current production and operational status is normal and there are no indications of delisting risks [1]

证券代码：603922 证券简称：金鸿顺 公告编号：2025-030 苏州金鸿顺汽车部件股份有限公司 关于终止筹划重大资产重组事项的投资者说明会召 开情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、投资者说明会召开情况 苏州金鸿顺汽车部件股份有限公司（以下简称"公司"）已于 2025 年 07 月 09 日 上 午 10:00-11:00 通 过 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/），以网络互动方式召开了公司关于终止筹划重大资产 重组事项的投资者说明会。公司董事长刘栩先生、独立董事叶少波先生、财务总 监周海飞先生、董事会秘书邹一飞先生就本次终止筹划重大资产事项的相关情况 沟通和交流，在信息披露允许的范围内就投资者普遍关注的问题进行了回答。 问题 1：您好刘董事长！关于 2025 年 2 季度经营业绩情况是否同比好转？ 答：您好！关于公司二季度经营情况及中报业绩情况，请您在 2025 年 8 月 30 日关注公司在指定 ...

Group 1 - TaiLong Pharmaceutical plans to apply for the registration and issuance of super short-term financing bonds not exceeding 800 million yuan, with a maturity of no more than 270 days, for purposes including replacing bank loans and supplementing working capital [1] - GuoXin Technology won a bid for a 46 million yuan automotive airbag ignition driver chip project, indicating its growing presence in the automotive semiconductor market [1] - GuoMai Technology expects a net profit increase of 60.52% to 100.33% for the first half of 2025, with a projected net profit of 125 million to 156 million yuan [2] Group 2 - ChangAluminum's subsidiary signed a 165 million yuan contract for the customized construction of a clinical and industrial base for a vaccine project, highlighting its involvement in the biopharmaceutical sector [3] - ZhongSalt Chemical acquired exploration rights for natural soda ash in Inner Mongolia for 929,000 yuan, expanding its resource base [4] - Six Kingdom Chemical announced the resignation of its deputy general manager, which may impact its operational strategy [5][6] Group 3 - FuYuan Pharmaceutical received a drug registration certificate for Bisoprolol Amlodipine tablets, indicating its expansion in the hypertension treatment market [7][8] - GuanShi Technology's subsidiary received a government subsidy of 7 million yuan, which is 45.29% of its net profit for the previous year, enhancing its financial position [9] - XiZhong Technology plans to repurchase shares worth between 75 million and 150 million yuan, aimed at employee stock ownership plans or equity incentives [10] Group 4 - BeiLu Pharmaceutical's subsidiary received approval for the raw material drug Iopromide, which is used as a contrast agent for various imaging examinations [12] - HongHui New Materials obtained a patent for a water-based protective paint for hardware parts, enhancing its product portfolio [13] - BoJi Pharmaceutical's subsidiary received two patents related to high bioavailability formulations, indicating innovation in biopharmaceutical technology [14] Group 5 - ChengJian Development received a cash dividend of 23.625 million yuan from its investment in Huaneng Capital, contributing to its investment income [15] - JiuZhou Pharmaceutical's subsidiary received a drug registration certificate for Sildenafil Citrate orally disintegrating tablets, expanding its product offerings in the erectile dysfunction treatment market [16] - RuiAng Gene's subsidiary received a government subsidy of 176,290 yuan, supporting its operational activities [17] Group 6 - FengFan Technology plans to acquire 100% equity of a subsidiary for 48 million yuan, indicating strategic expansion in the renewable energy sector [18] - AoJing Medical's subsidiary received a medical device production license, allowing it to manufacture absorbable surgical dressings [19] - TaiLin Bio's subsidiary won land use rights for an industrial site, facilitating its high-performance filter project [20] Group 7 - KaiPu Bio received a patent for a method and device for analyzing genomic copy number variations, enhancing its capabilities in molecular diagnostics [21] - Shanghai KaiBao received a drug registration certificate for Phlegm-Heat Clearing Capsules, which can be used in the treatment of COVID-19 symptoms [23] - TuoJing Life received two patents for high uniformity streptavidin applications, improving its diagnostic product stability [25] Group 8 - AnKe Bio's AK2024 injection received approval for clinical trials, marking a significant advancement in cancer treatment [26] - HuanYuan Pharmaceutical expects a net profit of 142 million to 160 million yuan for the first half of 2025, reflecting substantial growth [27] - JinHongShun terminated a major asset restructuring plan due to a lack of consensus among parties involved, impacting its strategic direction [28] Group 9 - HeZhan Energy signed a 177 million yuan contract for the sale of steel-concrete tower structures, indicating strong demand in the renewable energy sector [29] - InSai Group's acquisition plan for an 80% stake in ZhiZheTongXing was accepted by the Shenzhen Stock Exchange, indicating growth in its consulting business [30] - JiuDian Pharmaceutical received a drug registration certificate for Zinc Granules, enhancing its product line in gastrointestinal treatments [32] Group 10 - GuoYao Modern plans to publicly transfer a 51% stake in its subsidiary to optimize resource allocation [34] - GuoYao Modern's subsidiary received a drug registration certificate for Perindopril Indapamide tablets, expanding its hypertension treatment portfolio [36] - ZhongGong International signed a 175 million yuan engineering consulting service contract, showcasing its capabilities in project management [38] Group 11 - China Railway won contracts worth approximately 5.343 billion yuan for overseas construction projects, indicating its strong international presence [39] - JunPu Intelligent signed a framework contract for humanoid robot sales worth about 28.25 million yuan, reflecting growth in the robotics sector [41] - Sinopec's chairman resigned due to age, which may lead to changes in corporate governance [42] Group 12 - JiuFeng Energy's controlling shareholder plans to reduce their stake by up to 0.71%, indicating potential changes in ownership structure [44] - Zhejiang Oriental's subsidiary plans to establish a 1.74 billion yuan equity investment fund, focusing on strategic emerging industries [46] - ChenGuang New Materials received a government subsidy of 26 million yuan, significantly impacting its financial performance [48]

Core Viewpoint - Jin Hongshun (603922.SH) announced the termination of its major asset restructuring plan due to the inability to reach a consensus among the parties involved after extensive negotiations and due diligence [3]. Group 1: Announcement and Restructuring Plan - On October 23, 2024, Jin Hongshun disclosed its plan to acquire 95.79% of New Thinking Motor Co., Ltd. through a combination of issuing shares and cash payments, along with raising supporting funds [1]. - The company’s stock was suspended from trading on October 23, 2024, and resumed trading on November 6, 2024, after the board approved the restructuring plan [2]. - The restructuring was deemed significant under the regulations but did not constitute a related party transaction, nor did it change the actual control of Jin Hongshun [1][2]. Group 2: Financial Performance of Target Company - The target company, New Thinking, reported revenues of 465.12 million yuan, 878.92 million yuan, and 975.15 million yuan for the years 2022, 2023, and January-August 2024, respectively [4]. - The net profits for the same periods were -228.64 million yuan, 7.27 million yuan, and 93.18 million yuan, indicating a turnaround in profitability [4]. Group 3: Market Reaction - Following the resumption of trading on November 6, 2024, Jin Hongshun's stock hit the daily limit up for two consecutive trading days [5].